Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Nuclear Medicine

• Publication date

  2005-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 16157541
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis of N‐α‐(6‐Hydrazinonicotinoyl)‐Octreotide: A Precursor of a [99mTc] Complex

  2006cited by this paper
• Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.

  2005cited by this paper
• Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.

  2005influential reference
• 68Ga-labelled DOTA-derivatised peptide ligands

  2004cited by this paper
• Preparation and Biological Evaluation of Copper-64–Labeled Tyr3-Octreotate Using a Cross-Bridged Macrocyclic Chelator

  2004cited by this paper
• Radiometallo-labeled peptides in tumor diagnosis and therapy.

  2004influential reference
• An intrapatient comparison of 99mTc-EDDA/HYNIC-TOC with 111In-DTPA-octreotide for diagnosis of somatostatin receptor-expressing tumors.

  2003cited by this paper
• 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion

  2003cited by this paper
• Evaluating the clinical effectiveness of 90Y-SMT 487 in patients with neuroendocrine tumors.

  2003cited by this paper
• Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

  2003cited by this paper
• Clinical usefulness of 99mTc-EDDA/HYNIC-TOC scintigraphy in oncological diagnostics: a preliminary communication

  2003cited by this paper
• [99mTc]Demotate, a new 99mTc-based [Tyr3]octreotate analogue for the detection of somatostatin receptor-positive tumours: synthesis and preclinical results

  2002cited by this paper
• Radiolabeled peptides in the diagnosis and therapy of oncological diseases.

  2002influential reference
• Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC.

  2002cited by this paper
• PET imaging of somatostatin receptors: design, synthesis and preclinical evaluation of a novel 18F-labelled, carbohydrated analogue of octreotide

  2002cited by this paper
• Detection of neuroendocrine tumors: 99mTc-P829 scintigraphy compared with 111In-pentetreotide scintigraphy.

  2002influential reference
• PET imaging of somatostatin receptors using [68GA]DOTA-D-Phe1-Tyr3-octreotide: first results in patients with meningiomas.

  2001cited by this paper
• Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies.

  2000cited by this paper
• 99mTc-HYNIC-[Tyr3]-octreotide for imaging somatostatin-receptor-positive tumors: preclinical evaluation and comparison with 111In-octreotide.

  2000cited by this paper
• Detection of somatostatin receptor-positive tumours using the new 99mTc-tricine-HYNIC-d-Phe1-Tyr3-octreotide: first results in patients and comparison with 111In-DTPA-d-Phe1-octreotide

  2000cited by this paper
• Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

  2000cited by this paper
• Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy.

  2000cited by this paper
• Preclinical Comparison in AR4-2J Tumor-Bearing Mice of Four Radiolabeled 1,4,7,10-Tetraazacyclododecane-1,4,7,10-Tetraacetic Acid-Somatostatin Analogs for Tumor Diagnosis and Internal Radiotherapy.

  2000cited by this paper
• Diagnostic applications of radiolabeled peptides in nuclear endocrinology.

  1999influential reference
• 99m-Technetium-labelled peptide-HYNIC conjugates: effects of lipophilicity and stability on biodistribution.

  1999cited by this paper
• Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy.

  1999cited by this paper
• Radiometal‐Labelled Macrocyclic Chelator‐Derivatised Somatostatin Analogue with Superb Tumour‐Targeting Properties and Potential for Receptor‐Mediated Internal Radiotherapy

  1999cited by this paper
• Internalization of radiolabelled [DTPA0]octreotide and [DOTA0,Tyr3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy.

  1998influential reference
• Somatostatin receptor subtype specificity and in vivo binding of a novel tumor tracer, 99mTc-P829.

  1998cited by this paper
• The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-dPhe1,Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours

  1998cited by this paper
• Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats.

  1998cited by this paper
• Labeling cyclic glycoprotein IIb/IIIa receptor antagonists with 99mTc by the preformed chelate approach: effects of chelators on properties of [99mTc]chelator-peptide conjugates.

  1996cited by this paper
• Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.

  1995cited by this paper
• Effect of "co-ligand" on the biodistribution of 99mTc-labeled hydrazino nicotinic acid derivatized chemotactic peptides.

  1995cited by this paper
• (2-[18F]fluoropropionyl-(D)phe1)-octreotide, a potential radiopharmaceutical for quantitative somatostatin receptor imaging with PET: synthesis, radiolabeling, in vitro validation and biodistribution in mice.

  1994cited by this paper
• Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.

  1994cited by this paper
• Synthesis, radiochemistry and biological evaluation of a new somatostatin analogue (SDZ 219–387) labelled with technetium-99m

  1994cited by this paper
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

  1993cited by this paper
• Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats.

  1990cited by this paper
• Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.

  1989cited by this paper

• Synthesis and evaluation of [99mTc]Tc–octapa–necitumumab for targeted imaging of squamous non-small cell lung cancer

  2025cites this paper
• Modeling the effect of daughter migration on dosimetry estimates for [225Ac]Ac-DOTATATE.

  2025cites this paper
• Towards Radiolabeled EGFR-Specific Peptides: Alternatives to GE11

  2023cites this paper
• Deoxyfluorination of phenols for chemoselective ^18F-labeling of peptides

  2023cites this paper
• Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging

  2022cites this paper
• A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice

  2021cites this paper
• Structural modifications of amino acid sequences of radiolabeled peptides for targeted tumor imaging.

  2020cites this paper
• Single-Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals

  2020cites this paper
• Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours

  2019cites this paper
• Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model

  2019cites this paper
• Nuclear Medicine Procedures in Neuroblastoma

  2019cites this paper
• 68Ga-DOTATATE PET: temporal variation of maximum standardized uptake value in normal tissues and neuroendocrine tumours.

  2019cites this paper
• Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy

  2018cites this paper
• The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model

  2018cites this paper
• Radiolabeled Somatostatin receptor analogs in neuroendocrine tumor: novel applications and clinical indications for in-vivo tumor characterization

  2018cites this paper
• Development of PSMA inhibitors for molecular imaging and radio-guided surgery of prostate cancer

  2018cites this paper
• Radiolabelled peptides in medical imaging

  2018cites this paper
• The Value of Somatostatin Receptor Scintigraphy (SRS) in Patients with NETG1/G2 Pancreatic Neuroendocrine Neoplasms (p-NENs).

  2018cites this paper
• The tetraamine chelator outperforms HYNIC in a new technetium-99m-labelled somatostatin receptor 2 antagonist

  2018cites this paper
• Design, Synthesis, In Vitro, and Initial In Vivo Evaluation of Heterobivalent Peptidic Ligands Targeting Both NPY(Y1)- and GRP-Receptors—An Improvement for Breast Cancer Imaging?

  2018cites this paper
• Development of cyclic pentapeptide ligands for chemokine receptor targeting

  2017cites this paper
• Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors.

  2017cites this paper
• Up ‐ regulation of key molecules for targeted imaging and therapy

  2016cites this paper
• Upregulation of Key Molecules for Targeted Imaging and Therapy

  2016cites this paper
• Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma

  2016cites this paper
• Radiometallo-Labeled Peptides in Tumor Diagnosis and Targeted Radionuclide Therapy

  2016cites this paper
• Long-term efficacy of (90)Y-DOTATATE in patients with nonresectable pancreatic and small bowel neuroendocrine neoplasms.

  2016cites this paper
• Evaluation of neuroendocrine tumors with 99mTc-EDDA/HYNIC TOC.

  2016cites this paper
• Radiosynthesis and Preclinical Evaluation of 18F-Fluoroglycosylated Octreotate for Somatostatin Receptor Imaging.

  2016cites this paper
• Twins in spirit - episode I: comparative preclinical evaluation of ( 68 Ga)DOTATATE and

  2015cites this paper
• Novel radiolabeled peptides to improve breast and prostate cancer diagnosis by PET

  2015cites this paper
• Twins in spirit - episode I: comparative preclinical evaluation of [68Ga]DOTATATE and [68Ga]HA-DOTATATE

  2015cites this paper
• Radiolabeled Somatostatin Receptor Antagonists

  2015cites this paper
• Somatostatin Receptor Scintigraphy‐Spect

  2015cites this paper
• Molecular Imaging of Somatostatin Receptor‐Positive Tumors Using PET/CT

  2015cites this paper
• Radiolabeled new somatostatin analogs conjugated to DOMA chelator used as targeted tumor imaging agent: synthesis and radiobiological evaluation

  2015cites this paper
• Usefulness of Somatostatin Receptor Scintigraphy (99mTc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography

  2015cites this paper
• Preclinical Evaluation of a High-Affinity 18F-Trifluoroborate Octreotate Derivative for Somatostatin Receptor Imaging

  2014cites this paper
• Improved Kit Formulation for Preparation of 99mTc-HYNIC-TOC: Results of Preliminary Clinical Evaluation in Imaging Patients with Neuroendocrine Tumors

  2014cites this paper
• Gallium-68 DOTATOC PET/CT In Vivo Characterization of Somatostatin Receptor Expression in the Prostate

  2014cites this paper
• Radiolabeled novel peptide for imaging somatostatin-receptor expressing tumor: synthesis and radiobiological evaluation

  2014cites this paper
• Preparation and Biological Evaluation of [99mTc/EDDA/Tricine/HYNIC0, BzThi3]-Octreotide for Somatostatin Receptor-Positive Tumor Imaging

  2013influential citation
• Synthesis of Peptide Radiopharmaceuticals for the Therapy and Diagnosis of Tumor Diseases

  2013cites this paper
• Clinical applications of Gallium-68.

  2013cites this paper
• Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.

  2013cites this paper
• Ligand-Directed AAVP to Deliver a Therapeutic Transgene to Neuroendocrine Tumors of the Pancreas

  2013cites this paper
• SPECT/PET Imaging with Technetium, Gallium, Copper, and Other Metallic Radionuclides

  2013cites this paper
• Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.

  2012cites this paper
• Synthesis, radiolabeling, and preclinical evaluation of a new octreotide analog for somatostatin receptor‐positive tumor scintigraphy

  2012cites this paper
• The clinical value of scintigraphy of neuroendocrine tumors using (99m)Tc-HYNIC-TOC.

  2012cites this paper
• Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy

  2012cites this paper
• The Influence of Different Metal-Chelators on the Biological Profile of Nanoparticles for Gallium-68 Based Molecular Imaging

  2012cites this paper
• Pre-clinical evaluation of a new indirectly labeled ⁹⁹mTc-6-hydrazinopyridine-3-carboxylic acid (HYNIC)-depreotide with HYNIC as bifunctional chelator.

  2012cites this paper
• Tailored imaging of islet cell tumors of the pancreas amidst increasing options.

  2012cites this paper
• Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas.

  2012cites this paper
• Synthesis, characterization, conformational analysis of a cyclic conjugated octreotate peptide and biological evaluation of 99mTc-HYNIC-His3-Octreotate as novel tracer for the imaging of somatostatin receptor-positive tumors

  2012cites this paper
• Rationale for the use of radiolabelled peptides in diagnosis and therapy

  2012cites this paper
• Inhomogeneous activity distribution of 177Lu-DOTA0-Tyr3-octreotate and effects on somatostatin receptor expression in human carcinoid GOT1 tumors in nude mice

  2012cites this paper
• Specificity and sensitivity of 99mTc-EDDA/HYNIC-Tyr3-octreotide (99mTc-TOC) for imaging neuroendocrine tumors

  2012cites this paper
• Receptor affinity and preclinical biodistribution of radiolabeled somatostatin analogs.

  2012cites this paper
• Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment

  2011cites this paper
• Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

  2011cites this paper
• Radiolabeled peptide-receptor ligands in tumor imaging.

  2011cites this paper
• 68Ga-DOTATOC Versus 68Ga-DOTATATE PET/CT in Functional Imaging of Neuroendocrine Tumors

  2011influential citation
• Radiation Induces Up-Regulation of Somatostatin Receptors 1, 2, and 5 in Small Cell Lung Cancer In Vitro Also at Low Absorbed Doses

  2011cites this paper
• Synthesis, radiolabelling and biodistribution of HYNIC-Tyr3 octreotide: a somatostatin receptor positive tumour imaging agent

  2011cites this paper
• Antiproliferative Effects of 111In- or 177Lu-DOTATOC on Cells Exposed to Low Multiplicity-of-Infection Double-Deleted Vaccinia Virus Encoding Somatostatin Subtype-2 Receptor

  2010cites this paper
• [Lu]-DOTA-Tyr-octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma.

  2010cites this paper
• Receptor-mediated tumor targeting based on peptide hormones

  2010cites this paper
• Hydrazinonicotinic acid (HYNIC) – Coordination chemistry and applications in radiopharmaceutical chemistry

  2010cites this paper
• Technetium and gallium derived radiopharmaceuticals: comparing and contrasting the chemistry of two important radiometals for the molecular imaging era.

  2010cites this paper
• Applications of molecular imaging.

  2010cites this paper
• Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours.

  2010cites this paper
• Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study.

  2010cites this paper
• (99m)Tc and (111)In-labeling of small biomolecules: bifunctional chelators and related coordination chemistry.

  2010cites this paper
• Evaluation of 64Cu-labeled DOTA-d-Phe1-Tyr3-octreotide (64Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors

  2009cites this paper
• Molecular imaging targeting peptide receptors.

  2009cites this paper
• EFFECT OF SOMATOSTATIN ANALOGUE OCTREOTIDE IN MEDULLOBLASTOMA IN XENOGRAFT AND CELL CULTURE STUDY

  2009cites this paper
• Synthesis and characterization of an (111)In-labeled peptide for the in vivo localization of human cancers expressing the urokinase-type plasminogen activator receptor (uPAR).

  2009cites this paper
• Design considerations towards simultaneously radiolabeled and fluorescent imaging probes incorporating metallic species

  2009cites this paper
• Evaluation of radiological and clinical efficacy of ^{90}\textrm{Y-DOTATATE} therapy in patients with progressive metastatic midgut neuroendocrine carcinomas

  2009cites this paper
• Molecular imaging of neuroendocrine tumors

  2008cites this paper
• PET and SPECT Imaging of Tumor Biology: New Approaches towards Oncology Drug Discovery and Development.

  2008cites this paper
• Macrocyclic chelator-coupled gastrin-based radiopharmaceuticals for targeting of gastrin receptor-expressing tumours

  2008cites this paper
• Initial Direct Comparison of 99mTc-TOC and 99mTc-TATE in Identifying Sites of Disease in Patients with Proven GEP NETs

  2008cites this paper
• New Pansomatostatin Ligands and Their Chelated Versions: Affinity Profile, Agonist Activity, Internalization, and Tumor Targeting

  2008cites this paper
• In vitro comparison of renal handling and uptake of two somatostatin receptor-specific peptides labeled with indium-111

  2008cites this paper
• Agonist-antagonist dilemma in molecular imaging: evaluation of a monomolecular multimodal imaging agent for the somatostatin receptor.

  2008cites this paper
• True radiotracers: are we approaching theoretical specific activity with Tc-99m and I-123?

  2008cites this paper
• Intracellular degradation of somatostatin‐14 following somatostatin‐receptor 3‐mediated endocytosis in rat insulinoma cells

  2008cites this paper
• Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?

  2007cites this paper
• Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14).

  2007cites this paper
• Bombesin and Neurotensin Receptor Targeting Using Radiolabeled Peptide Analogs

  2007cites this paper
• Endokrine Tumoren des gastroenteropankreatischen Systems

  2007cites this paper
• Preclinical evaluation of somatostatin analogs bearing two macrocyclic chelators for high specific activity labeling with radiometals

  2007cites this paper
• Radio-guided surgery with the use of [99mTc-EDDA/HYNIC]octreotate in intra-operative detection of neuroendocrine tumours of the gastrointestinal tract

  2007cites this paper
• Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.

  2007cites this paper
• Nuclear imaging of neuroendocrine tumours.

  2007cites this paper
• Radiochemistry and radiopharmaceuticals

  2006cites this paper
• Synthesis, development and preclinical comparison of two new peptide based freeze-dried kit formulation 99mTc-EDDA-Tricine-HYNIC-TOC and 99mTc-EDDA-Tricine-HYNIC-TATE for somatostatin receptor positive tumor scintigraphy

  2006cites this paper